Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care
Join us for this case-based, interactive on-demand program featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma.
Updates to Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Live satellite symposium with a panel of experts discussing current guidelines and latest clinical evidence for the management of patients with multiple myeloma including expert guidance to help inform treatment decisions and therapy sequencing.
Archived NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2025
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia

As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis.

Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease

With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.

Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies

Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.

Pages

Subscribe to RSS - Multiple Myeloma